Pfizer Strikes $400M Deal To End Shareholder Suit
Pfizer Inc. has reached a $400 million settlement to avoid an upcoming trial in a class action claiming the company misled investors about an alleged off-label drug marketing scheme, the pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article